A Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of Oral ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of Oral ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis
A randomized, double-blind, placebo-controlled phase III study evaluating the efficacy and safety of oral ICP-332 in subjects with moderate to severe atopic dermatitis
Inclusion Criteria:
Male or female subjects between 18 and 75 years of age.
Clinical diagnosis of chronic atopic dermatitis (also known as atopic eczema) for at least 1 year
Documented recent history of inadequate response to TCS or TCI, or for whom topical treatments are otherwise medically inadvisable.
Subjects must meet the following criteria for disease activity:
Women of childbearing potential (WOCBP) and Men must agree
5. Women of childbearing potential (WOCBP) and Men must agree to contraception. 6. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
Exclusion Criteria:
pengcheng.lei@innocarepharma.com+86 18501252185
Hefei, Anhui 230022, China
Beijing, Beijing Municipality 100020, China
Beijing, Beijing Municipality 100050, China
Beijing, Beijing Municipality 100730, China
Chongqing, Chongqing Municipality 400016, China
Chongqing, Chongqing Municipality 400021, China
Luoyang, Henan 471000, China
Wuhan, Hubei 430022, China
Hohhot, Inner Mongolia 010050, China
Shenyang, Liaoning 110001, China
Tianjin, Tianjin Municipality 300120, China
Hangzhou, Zhejiang 310009, China
Wenzhou, Zhejiang 325000, China